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Abstract
Background Colon cancer (CC) patients commonly suffer
declines in muscle mass and aerobic function. We hypoth-
esised that CC would be associated with reduced muscle
mass and mitochondrial enzyme activity and that curative
resection would exacerbate these changes.
Methods We followed age-matched healthy controls and
CC patients without distant metastasis on radiological im-
aging before and 6 weeks after hemi-colectomy surgery.
Body composition was analysed using dual energy X-ray
absorptiometry. Mitochondrial enzyme activity and protein
concentrations were analysed in vastus lateralis muscle
biopsies.
Results In pre-surgery, there were no differences in lean mass
between CC patients and age-matched controls (46.1+32.5
vs. 46.1+37.3 kg). Post-resection lean mass was reduced in
CC patients (43.8+30.3 kg, P<0.01). When comparing
markers of mitochondrial function, the following were ob-
served: pyruvate dehydrogenase (PDH) activity was lower in
CC patients pre-surgery (P<0.001) but normalized post-
resection and cytochrome c oxidase and pyruvate dehydroge-
nase E2 subunit protein expression were lower in CC patients
pre-surgery and not restored to control values post-resection
(P<0.001). Nuclear factor kappa-B, an inflammatory marker,
was higher in CC patients pre-surgery compared to controls
(P<0.01), returning to control levels post-resection.
Conclusion Muscle mass was affected by surgery rather
than cancer per se. PDH activity was however lower in
cancer patients, suggesting that muscle mass and mitochon-
drial enzyme activity are not inextricably linked. This re-
duction in mitochondrial enzyme activity may well
contribute to the significant risks of major surgery to which
CC patients are exposed.
Keywords Cancer . Muscle . Mitochondria . Pyruvate
dehydrogenase
1 Introduction
Colorectal cancer (CRC) is a common condition with ap-
proximately 600,000 new cases per annum worldwide [1].
Over the past 40 years, CRC has increased in prevalence by
over 40 % [2] accounting for 42,000 deaths between 2001
and 2003 in England and Wales [3]. CRC is now the third
most common cancer and second leading cause of cancer-
related death in the UK [4].
CRC patients may present at the clinic with cachexia
syndrome [5, 6]; 35 to 60 % of CRC patients show some
degree of muscle wasting and 28 % lose >5 % of their body
weight in the 6 months preceding diagnosis [7]. Moreover,
CRC patients also frequently display symptoms of chronic
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fatigue and report reductions in physical capacity [8, 9].
Indeed, 60–96 % of (former) cancer patients complain of
fatigue during and/or after treatment [8, 9], and although the
extent of fatigue decreases gradually in disease-free survivors,
30 % of cancer survivors still report serious complaints of
fatigue 3 years after completion of medical treatment [8, 9].
Despite advances in adjuvant and neo-adjuvant treat-
ments, surgical resection remains the mainstay of curative
treatment. However, surgical resection itself places addition-
al metabolic demands upon the body (including skeletal
muscle) which can exacerbate symptoms related to the ini-
tial cancer burden [10]. Although various researchers have
followed changes in muscle mass and markers of muscle
protein breakdown and synthesis in the immediate post-
operative period [10–12], to our knowledge, there are no
studies exploring the effect of colon cancer (CC) on indices
of cellular skeletal muscle oxidative capacity in patients
both before and after surgery, compared to healthy age-
matched volunteers.
In addition to the simple loss of muscle, skeletal muscle
pathophysiology is a feature of a number of chronic con-
ditions including cancer, chronic obstructive pulmonary dis-
ease (COPD), diabetes and congestive heart failure [13–16],
representing a major contribution to adverse outcomes in
these conditions. In these instances, skeletal muscle has
been shown to display corresponding morphological and
biochemical changes [13–15, 17–21]. For instance, in the
skeletal muscle of COPD patients', mitochondrial content/
density and the activities of the mitochondrial enzymes
cytochrome c oxidase and succinate dehydrogenase are
reduced with associated declines in exercise capacity and
increased symptoms of fatigue [14, 16]. Adenosine triphos-
phate (ATP) production is also impaired in these individuals
through a reduced ability of pyruvate dehydrogenase (PDH)
to convert pyruvate to acetyl-CoA, a process which may be
mediated by pyruvate dehydrogenase kinase isozyme 4
(PDK4), the enzyme responsible for inactivating PDH. Al-
though these processes are well documented in conditions
such as COPD, little is known about the effect of cancer on
such vital pathways in skeletal muscle.
In addition to the dysregulation outlined above, in states
of inflammation and ischaemia, the inflammatory cytokine
nuclear factor kappa-B (NFκB) is upregulated playing an
important role in modulating cellular responses [22]. Al-
though there is a large body of evidence supporting the
upregulation of NFκB in the rapid loss of muscle protein
seen in vitro and in animal models of cancer [23], only
recently has evidence emerged suggesting that NFκB is
upregulated in the skeletal muscle of patients with gastric
cancer [24].
The aim of this study was therefore to determine the
effect of CC on muscle mass and indices of mitochondrial
enzyme expression/activity and muscle inflammation before
and after surgery. We hypothesised that CC would be asso-
ciated with increased cellular inflammation, reduced muscle
mass and reduced mitochondrial enzyme activity and that
these changes would be exacerbated by curative resection,
despite removal of tumour burden.
2 Materials and methods
2.1 Subject characteristics
We recruited two groups of subjects consisting of healthy
volunteers (70.7±1.6 years old, four males, four females,
body mass index (BMI) 26.2±1.0 kg m−2) and patients with
colon cancer (62.5±8.3 years old, four males, four females,
BMI 27.6±1.6 kg m−2) presenting to colorectal out-patients,
excluding those with distant metastasis on pre-operative
staging. The healthy volunteers were asked to undergo a
single acute study, and the CC patients were studied pre-
operatively and 6 weeks post-resection (open hemi-
colectomy) prior to any chemotherapy regime. All CC
patients underwent uncomplicated recoveries following
hemi-colectomy. Before beginning the study, all subjects
were screened using a medical questionnaire, physical ex-
amination and resting ECG. Exclusion criteria for patients
and controls were metabolic, respiratory or cardiovascular
disorders or any other contraindications to a healthy status.
As a condition of entry to the study, all subjects had normal
blood chemistry and were normotensive (BP <140/90). All
subjects gave their written, informed consent to participate
in the study. The study was approved by the local NHS REC
committee and the University of Nottingham Ethics Com-
mittee and complied with the Declaration of Helsinki.
2.2 Acute studies
Subjects were instructed to refrain from unaccustomed ex-
ercise for 72 h and from alcohol and caffeine for 24 h before
study days. All subjects fasted from 2100 hours the night
before, with water ad libitum, and reported to the laboratory
at 0900 hours. Body composition was measured by dual-
energy X-ray absorptiometry (Lunar Prodigy II, GE Medical
Systems), and a single muscle biopsy of vastus lateralis was
taken using the conchotome technique under post-
absorptive conditions at the beginning of the acute study.
2.3 Immunoblotting
Muscle biopsies (~10–20 mg) were homogenised with scis-
sors in ice-cold extraction buffer (10 μl/mg−1) containing
50 mM Tris–HCl (pH 7.4), 1 mM EDTA, 1 mM EGTA,
50 mM NaF, 0.5 mM activated sodium orthovanadate (all
from Sigma-Aldrich, Poole, UK) and a complete protease
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inhibitor cocktail tablet (Roche, West Sussex, UK). Homo-
genates were rotated on a Vibramax for 10 min at 4°C then
centrifuged at 10,000 × g for 10 min at 4°C, before recovery
of supernatants representing sarcoplasmic fractions. Brad-
ford assays were used to determine sarcoplasmic protein
concentrations after which samples were standardised to
1 μg/μl−1 by dilution with Laemmli loading buffer in order
to measure relative protein concentrations of pan actin,
myosin, NFκB, pyruvate dehydrogenase E2 subunit (PDH-
E2), PDK4 and cytochrome c oxidase. Samples were mixed
and heated at 95°C for 5 min before 15 μg of protein/lane
was loaded on to Criterion XT Bis–Tris 12 % SDS-PAGE
gels (Bio-Rad, Hemel Hempstead, UK) for electrophoresis
at 200 V for ~60 min. Gels were equilibrated in a transfer
buffer (25 mM Tris, 192 mM glycine, 10 % methanol) for
30 min before proteins were electroblotted on to 0.2-μm
PVDF membranes (Bio-Rad) at 100 V for 30 min. After
blocking with 5 % low-fat milk in Tris-buffered saline
(TBS-T) and 0.1 % Tween-20 (both from Sigma-Aldrich,
Poole, UK) for 1 h, membranes were rotated overnight with
a primary antibody (PDK4, PDH-E2, cytochrome c oxidase,
Abcam, UK; pan actin, myosin, NFκB, Sigma-Aldrich, UK)
against the aforementioned targets at a concentration of
1:2,000 at 4°C. Membranes were washed (3×5 min) with
TBS-T and incubated for 1 h at room temperature with HRP-
conjugated anti-rabbit secondary antibody (New England
Biolabs, UK), before further washing (3×5 min) with
TBS-T and incubation for 5 min with ECL reagents (en-
hanced chemiluminescence kit, Immun-Star, Bio-Rad).
Blots were imaged and quantified by assessing peak density
after ensuring bands were within the linear range of detec-
tion using the ChemiDoc XRS system (Bio-Rad, Hemel
Hempstead, UK). Protein concentration was corrected for
loading anomalies to eukaryotic translation initiation factor
4E or glyceraldehyde-3-phosphate dehydrogenase depen-
dent upon the expected size of the target protein.
2.4 Pyruvate dehydrogenase activity
PDH enzyme activity was measured using a PDH Enzyme
Activity Microplate Assay Kit (MitoSciences, USA). The
protocol was followed according to manufacturer's instruc-
tion. In brief, 10 mg of vastus lateralis muscle was homo-
genised in 100 μl phosphate-buffered saline. Sample protein
concentration was measured using the Bradford assay be-
fore detergent was added to the sample to solubilise intact
functional PDH. The samples were then incubated on ice for
10 min before centrifuging at 10,000 × g for 10 min at 4°C.
Sample supernatant was then diluted with buffer to achieve
a dilution of 0.2 μg/200 μl; 200 μl of solubilised, diluted
sample was added to each well of the microplate before the
microplate was incubated for 3 h prior to washing with a
stabiliser. Finally, assay solution was added to the plate
before reading the absorbance of each well at 450 nm using
a kinetic programme with 60 s between reads (Multiskan
Ascent plate reader, Ascent software V 2.6, Thermo Scien-
tific, UK).
2.5 Statistical analysis
Results are reported as means ± SEM. Variables were ana-
lysed with one-way ANOVA to assess significant differ-
ences between the groups. Post-hoc analyses were
performed with Tukey's method, and P<0.05 was the ac-
cepted level of statistical significance.
3 Results
3.1 Body composition
Patients with CC were matched for age with healthy
controls. BMI was not significantly different between
the two groups (26.2±1.0 kg m−2, healthy controls,
and 27.6±1.6 kg m−2, colon cancer patients) and did
not change significantly after surgery in the cancer
patients. There were no significant differences in whole
body (46.1±3.7 vs. 46.1±3.3 kg) or appendicular lean
mass (20.7±1.6 vs. 19.4±1.5 kg) between the healthy
controls and the cancer patients before surgery although
the cancer patients did have significantly lower whole
body (43.8±3.0 kg, P<0.01) and appendicular (18.0±
1.4 kg, P<0.05) lean mass post-resection (Table 1).
3.2 Immunoblotting
Protein expression of NFκB, a marker of muscle inflamma-
tion, was significantly higher in pre-operative cancer
patients compared to the healthy control subjects (1.42±
0.32 vs. 0.50±0.07, P<0.01). Post-resection levels of NFκB
were reduced to a value not significantly different to that of
the healthy controls (0.75±0.13 vs. 0.50±0.07, Fig. 1). Pro-
tein expressions of both pan actin and total myosin were not
significantly different between the healthy controls and can-
cer patients either before or after resection, with neither
surgery or cancer having any significant effect on the pro-
tein expression of either of these targets (pan actin, 0.45±
0.06 vs. 0.46±0.08 and 0.56±0.12; total myosin, 0.98±0.08
vs. 0.75±0.12 and 0.74±0.07). PDH-E2 protein expression
was significantly higher in the healthy controls than in the
cancer patients both before and after resection (2.14±0.20
vs. 0.89±0.08 and 0.80±0.12, P<0.001) with no significant
difference between values in the cancer patients pre- and
post-operatively (Fig. 2). Protein expression of PDK4 was
not significantly different between the healthy controls and
cancer patients either before or after resection (1.36±0.08
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vs. 1.35±0.08 and 1.37±0.06). Cytochrome c oxidase pro-
tein expression was significantly higher in the healthy
controls than in the cancer patients both before and after
resection (1.26±0.22 vs. 0.56±0.09 and 0.42±0.07, P<0.01
and P<0.001, respectively) with no significant difference
between the cancer patients pre- and post-operatively
(Fig. 3).
3.3 Pyruvate dehydrogenase enzyme activity
PDH enzyme activity was significantly lower in pre-
operative cancer patients compared to the healthy controls
(0.16±0.06 vs. 1.00±0.11, P<0.001). Post-resection PDH
enzyme activity in the cancer patients was restored to values
not different to that of the healthy controls (1.00±0.15 vs.
1.00±0.11, Fig. 4).
4 Discussion
Although surgery represents the only cure for CC, it is still
associated with a 30-day mortality rate of approximately
4 % [25]. Adequate skeletal muscle mass and function
(i.e., aerobic capacity) have been associated with the inci-
dence and severity of complications in the post-operative
period and may ensure survival following major surgical
resection [26]. In this study, we have demonstrated that
although lean body mass in healthy controls and CC patients
was not significantly different, indices of mitochondrial
enzyme activity in skeletal muscle are lower in patients with
colon cancer prior to curative surgical resection compared to
healthy age-matched controls. Using a longitudinal study
design, we investigated the effects of CC and subsequent
surgical resection (in comparison to a healthy age-matched
control group) on muscle mass and indices of mitochondrial
function. Specifically, we have demonstrated that protein
concentrations of the mitochondrial enzymes PDH and cy-
tochrome c oxidase (COX) and the activity of PDH are
lower in the vastus lateralis of individuals with CC, despite
there being no measurable cachexia. Moreover, PDH activ-
ity, but not PDH and COX protein concentrations, returned
to control levels 6 weeks after resection, despite significant
declines in muscle mass. Finally, depressions in PDH activity
and the subsequent post-surgery ‘normalisation’ inversely
reflected the protein concentration of the pro-inflammatory
transcription factor, NFκB.
Previous studies analysing changes in gene expression in
the skeletal muscle of tumour-bearing mice showed a re-
duced expression of a number of genes involved in encod-
ing the key proteins in mitochondrial energy production.
Amongst these, two genes encoding the pyruvate dehydro-
genase complex were shown to be reduced in tumour-
bearing mice compared to healthy controls [27]. Pyruvate
dehydrogenase is crucial in enabling carbohydrate (CHO) to
enter the tricarboxylic acid cycle and for achieving higher
work intensities [28]. At intensities below about 75 % of
Table 1 Body composition data
for healthy controls and cancer
patients pre- and post-resection
Values are means ± SEM. Anal-
ysis was done via ANOVAwith
Tukey's post-analysis
*P<0.01 (vs. cancer patients
post-surgery)
Healthy controls Cancer patients Cancer patients
Pre-surgery Post-surgery
Age (years) 70.7±1.6 62.5±8.3 62.7±8.3
BMI (kg m−2) 26.2±1.0 27.6±1.6 26.9±1.4
Total lean mass (kg) 46.1±3.7* 46.1±32.5* 43.8±3.0
Appendicular lean mass (kg) 20.7±1.6* 19.4±1.5* 18.0±1.4
Fig. 1 Protein expression of NFκB in healthy controls and cancer
patients before and after resection. Values are means ± SEM for eight
control subjects and eight cancer patients. **P00.007. Analysis was
done via ANOVA with Tukey's post-analysis
Fig. 2 Protein expression of pyruvate dehydrogenase E2 subunit in
healthy controls and cancer patients before and after resection. Values
are means ± SEM for eight control subjects and eight cancer patients.
***P<0.001, vs. healthy controls. Analysis was done via ANOVAwith
Tukey's post-analysis
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maximum, energy is generated within skeletal muscle by the
oxidation of free fatty acids and CHO, whereas at higher
workloads, CHO becomes the primary fuel source [29].
Reductions in exercise capacity and early onset of anaerobic
metabolism and lactic acidosis on exercising have been
shown to be predictors of increased mortality after major
surgery [30–33]. Additionally, in human studies, several
investigations have shown that a number of pathologies
such as COPD and type II diabetes can result in limitations
of skeletal muscle oxidative capacity [14–16, 18–21].
Our findings suggest that the capacity of PDH for oxida-
tive CHO disposal is significantly lower in colon cancer
before tumour resection, albeit returning to normal 6 weeks
post-resection. One possible mechanism for the reductions
in PDH activity would be through a reduction in PDH
protein expression. However, PDH protein expression was
lower in cancer patients both prior to and following hemi-
colectomy surgery compared to controls. Although protein
abundance may not return to normal so soon after tumour
resection, these results indicate that factors other than PDH
protein expression are responsible for the diminution seen in
PDH activity before surgery. Moreover, protein concentra-
tions of PDK-4, the kinase primarily responsible for phos-
phorylating and inactivating PDH in skeletal muscle [13, 34,
35], did not follow PDH activity, instead acting similarly to
PDH protein showing lower abundance regardless of tu-
mour burden. This suggests that in the presence of colon
cancer, PDH dysfunction is not mediated through reductions
in PDH or increases in PDK-4.
One possible alternative mechanism by which PDH ac-
tivity is lowered in colon cancer may relate to our observa-
tions surrounding the pro-inflammatory transcription factor
NFκB. Indeed, previous researchers have postulated that
lipopolysaccharide-induced endotoxaemia in rats may lead
to a reduction in pyruvate dehydrogenase activity [36],
while NFκB activity has been shown to be increased in
the muscle of cancer patients [24] and implicated in the
rapid weight loss seen in these individuals [37]. In our study,
NFκB expression was higher in CC patients pre-resection
than in control subjects, with a return to normal 6 weeks
after resection. These variations in NFκB expression closely
reflected changes in PDH activity, indicating a possible
association between a low PDH activity and the ongoing
inflammatory milieu within the skeletal muscle of CC
patients.
As with PDH protein, cytochrome c oxidase was also less
abundant in the skeletal muscle of CC patients pre- and post-
operatively when compared to that of healthy controls. Due to
its position at the end of the electron transport chain, deficien-
cies in cytochrome c oxidase expression and function may
have a profound impact on oxidative ATP generation and
health, with deficiencies being described in a number of con-
ditions including encephalomyopathies, Leigh syndrome, lac-
tic acidosis and hypertrophic cardiomyopathies; all of which
can be fatal [38]. Although we did not specifically assay the
activity of cytochrome c oxidase, its low expression suggests
that in skeletal muscle, its activity may also be lower and
oxidative ATP production depressed in CC, leading to deficits
in skeletal muscle energy production. These findings indicate
that oxidative energy production within the mitochondrion is
not only limited by an inability of CHOs to enter the tricar-
boxylic acid cycle through reductions in PDH expression and
activity but also through limitations in cytochrome c oxidase
expression and oxidative ATP generation in the mitochondrial
inner membrane.
Fig. 3 Protein expression of cytochrome c oxidase in healthy
controls and cancer patients before and after resection. Values
are means ± SEM for eight control subjects and eight cancer patients.
**P00.001, vs. healthy controls. Analysis was done via ANOVA with
Tukey's post-analysis
Fig. 4 Pyruvate dehydrogenase activity in 10 mg of muscle from
healthy controls and cancer patients before and after resection. Values
are means ± SEM for eight control subjects and eight cancer patients.
**P<0.001, vs. healthy controls. Analysis was done via ANOVAwith
Tukey's post-analysis
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Colon cancer and major surgical operations are both
frequently associated with losses of skeletal muscle mass
which may confer an increased risk of perioperative com-
plications and mortality [10, 26, 37, 39]. In this study, pre-
resection CC patients and age-matched controls demonstrat-
ed no significant differences in lean mass or BMI. Although
this is at odds with much of the literature published in this
field, this present study contains a select group of patients
without distant metastasis in the earlier stages of CRC and
this may well account for our inability to show marked
changes in whole body lean mass between controls and
patients pre-operatively. However, 6 weeks post-resection
whole-body lean mass was reduced in CC patients (46.1±
3.3 vs. 43.8±3.0 kg, P<0.01), although this was not paral-
leled by decreases in expression of the structural proteins
myosin or actin. This finding mirrors the observations of
previous researchers [10] and may be due to a combination
of the trauma and catabolic effect of surgery [40] as well as
patient inactivity and/or reduced dietary intake in the post-
operative period [41]. There is strong evidence that muscle
mass is closely correlated with maximal aerobic perfor-
mance in health and that maximal loss of muscle occurs
14 days post-surgery [10, 42–44]. Our findings however
suggest that although mitochondrial oxidative capacity is
beginning to normalise 6 weeks post-resection, muscle mass
is still diminished compared to pre-operative values. These
findings will have contrasting effects on global aerobic
performance, implying that in CC muscle mass may not be
as tightly linked to maximal aerobic performance as in
health.
In this study, we have shown that in CC indices of human
skeletal muscle oxidative capacity are lower than in healthy
age-matched controls, with reductions in PDH and cyto-
chrome c oxidase expression and PDH activity. These find-
ings are similar to the changes seen in mitochondrial
oxidative capacity in other systemic disease states. In con-
junction with the reduction in muscle mass in the post-
operative period reported by us and other researchers [10],
these cellular changes may well contribute to the significant
risks of major surgery to which CC patients are exposed.
5 Study limitations
We acknowledge that there are limitations to our elected
study design. Firstly, this is a pilot study presenting prelim-
inary findings following a small group of patients through
the perioperative period; therefore, larger studies need to be
undertaken to confirm the changes observed in measured
markers of inflammation and cellular metabolic function.
Second, although groups were matched with no statistically
significant difference in age between patients and controls,
controls were on average 8 years older. We accept that this
increase in age could be expected to be associated with a
reduced muscle mass in the control population and may in
itself result in derangements of inflammatory and cellular
metabolic function. Finally, patients were studied for a sec-
ond time 6 weeks after colorectal surgery. Although all
made uncomplicated progress in the post-operative period,
it could be argued that the inflammatory response to surgery
had not completely subsided at this time point and that the
second study would have been better undertaken at a later
post-operative time point.
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